Venetoclax test in women with specific non-Hodgkin lymphomas
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This Phase 1 study tests how venetoclax affects certain hormone pills (ethinyl estradiol and levonorgestrel) in women with different non-Hodgkin lymphomas. It’s mainly looking at safety and drug interactions, which could help guide treatment for people who need hormone-based contraception.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have relapsed or refractory non-Hodgkin’s lymphoma (NHL).
- Your NHL subtype is one of these: DLBCL, follicular lymphoma, lymphoplasmacytic lymphoma, mantle cell lymphoma, marginal zone lymphoma, T-PLL, or Waldenström’s macroglobulinemia.
- Your general condition (ECOG) is 0 to 2, meaning you’re able to do self-care and most daily activities.
- Your bone marrow, liver, kidneys, and blood clotting tests meet the study’s limits.
- You are a woman who is considered “not able to get pregnant” under the study rules.
- You do not have certain excluded conditions like active serious heart disease or lymphoma in the brain/spinal cord.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests how well venetoclax (a targeted pill for CLL) works in people whose CLL has come back or hasn’t responded. It also closely tracks early changes in the CLL cells to better understand what happens during treatment.
This trial tests giving venetoclax to people with CLL who are already taking a BTK inhibitor and have stable disease. The goal is to see if adding venetoclax can help eliminate any remaining CLL cells.
This trial tests a targeted pill called venetoclax for people whose hairy cell leukemia has returned after other treatments. It aims to see if venetoclax can help control the disease and improve blood counts.
This study checks how the body handles venetoclax when it's given as a liquid made from crushed tablets. It's for children and young adults with blood cancers who already take venetoclax crushed or through a feeding tube.
This Phase 2 trial tests whether adding venetoclax to a chemotherapy plan works better for Philadelphia chromosome–negative acute lymphoblastic leukemia (ALL). It may help people achieve deeper remission by targeting leukemia cells in a different way than chemotherapy alone.
This trial tests whether adding venetoclax (a pill that targets cancer cells) to the standard chemotherapy regimen before a stem cell transplant improves outcomes for people with high-risk acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). It is for patients aged 12–60 whose cancer has specific high-risk features and who have a matched donor.
Hear when a new Hematologic Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.